Decoding NOTCH1: From T-Cell Development Guardian to Driver of Pediatric T-Cell Lymphoblastic Lymphoma

T-cell lymphoblastic lymphoma (T-LBL) is an aggressive malignancy of immature T-cells accounting for a substantial proportion of pediatric non-Hodgkin lymphoma cases. Current chemotherapeutic regimens achieve five-year event-free survival rates of 80-90%, yet relapse occurs in approximately 20% of patients and remains a major therapeutic challenge. This underscores the need for improved, molecularly informed treatment strategies. Recent genomic profiling has highlighted the central role of <i>NOTCH1</i> signaling in T-LBL pathogenesis. <i>NOTCH1</i>, a transmembrane receptor critical for T-cell differentiation and maturation, requires tightly regulated activation during normal thymocyte development. Dysregulated signaling disrupts this balance, driving aberrant proliferation and impaired differentiation, characteristics of malignant transformation. While activating mutations have long been recognized as key oncogenic events, the recent identification of recurrent <i>NOTCH1</i> translocations, associated with adverse outcomes, reveals an additional mechanism of pathway activation. These findings reinforce <i>NOTCH1</i> as a pivotal oncogenic hub in T-cell malignancies and a compelling target for therapeutic intervention. This review synthesizes current insights into the molecular landscape of pediatric T-LBL, with a focus on the biological and clinical implications of <i>NOTCH1</i> mutations and translocations. Furthermore, we examine emerging approaches to therapeutically exploit aberrant <i>NOTCH1</i> signaling for the more precise and effective treatment of this disease and formulate outstanding research questions.